Its unique ability to inhibit CK-1ε helps to maintain the number and function of regulatory T-cell in patients via the TCF-1 and FoxP3 pathway, reducing immune-mediated side effects in the treatment of hematologic malignancies (21). This evidence concerns the gene FOXP3 and hematologic disorder.